Page 157 - 2022_02-Haematologica-web

RHOA mutation analysis in early lymphoma diagnosis
24. Nguyen TB, Sakata-Yanagimoto M, Fujisawa M, et al. Dasatinib Is an effective treatment for angioimmunoblastic T-cell lymphoma. Cancer Res. 2020;80(9):1875- 1884.
25. Attygalle AD, Diss TC, Munson P, Isaacson PG, Du MQ, Dogan A. CD10 expression in extranodal dissemination of angioim- munoblastic T-cell lymphoma. Am J Surg Pathol. 2004;28(1):54-61.
26. Vallois D, Dobay MP, Morin RD, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lym-
phomas. Blood. 2016;128(11):1490-1502. 27. Rohr J, Guo S, Huo J, et al. Recurrent acti- vating mutations of CD28 in peripheral T- cell lymphomas. Leukemia. 2016;
al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lym- phomagenesis. Cancer Cell. 2011;20(1):25-
30(5):1062-1070. 38.
28. Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, et al. Activation of RHOA- VAV1 signaling in angioimmunoblastic T- cell lymphoma. Leukemia. 2018;32(3):694- 702.
29. Couronné L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95-96.
30. Quivoron C, Couronné L, Della Valle V, et
31. Schwartz FH, Cai Q, Fellmann E, et al. TET2 mutations in B cells of patients affect- ed by angioimmunoblastic T-cell lym- phoma. J Pathol. 2017;242(2):129-133.
32. Ch'ang HJ, Su IJ, Chen CL, et al. Angioimmunoblastic lymphadenopathy with dysproteinemia--lack of a prognostic value of clear cell morphology. Oncology. 1997;54(3):193-198.
haematologica | 2022; 107(2)
499